Praxis Precision Medicines Cash Hits $1.3B, Two PDUFA Dates Set

Praxis Precision Medicines (NASDAQ: PRAX) reported on 9 November 2026 that its cash, cash equivalents and marketable securities reached approximately $1.3 billion as of 30 September 2026, up $359.9 million from $926.1 million at 31 December 2025. The company said the increase came mainly from net proceeds of a January 2026 follow-on public offering and interest income on marketable securities, partly offset by cash used in operations. Two FDA reviews are running: relutrigine carries a PDUFA target action date of 27 December 2026, and ulixacaltamide 29 January 2027.

Context — Why Two PDUFA Dates Matter for PRAX Now

Praxis is a fully integrated CNS precision neuroscience company with four late-stage product candidates, two of which sit under active FDA review. The company framed the period as a transition from clinical-stage development toward commercial operations, with CEO Marcio Souza saying the teams are working to bring relutrigine and ulixacaltamide to patients who need new options.

The company said the relutrigine commercial team is fully hired and the ulixacaltamide sales force is expected to be in place this quarter. That sequencing matters: staffing spend lands before any revenue, which is why general and administrative costs jumped in the quarter.

Both programs carry Breakthrough Therapy Designation. Ulixacaltamide received that designation in December 2025 and is the first and only investigational therapy the company says has shown positive results in a Phase 3 program in essential tremor. Relutrigine holds Breakthrough Therapy and Orphan Drug designations and would be eligible for a Pediatric Review Voucher if approved.

Essential tremor affects roughly seven million patients in the U.S., according to the company, and it describes ulixacaltamide as the most advanced asset in its Cerebrum small molecule platform. Relutrigine targets SCN2A and SCN8A developmental and epileptic encephalopathies, where the company says it would be the first therapy if approved.

The macro backdrop is not in the report, but the balance sheet matters on its own terms: a January 2026 equity raise added capital while the FDA clock runs, and the company now says that capital funds operations into 2028.

Data — What the Numbers Show

Revenue is absent from the income statement because Praxis has no approved product. The relevant figures are spending, losses and cash.

Metric	Q3 2026	Q3 2025
Research and development	$64.2M	$65.8M
General and administrative	$42.7M	$12.6M
Net loss	$94.2M	$73.9M
Net loss per share	$3.23	$3.36

Research and development fell $1.6 million year over year, which the company attributed to $8.8 million lower Cerebrum expenses, partly offset by $7.0 million higher personnel-related costs. General and administrative expenses rose $30.1 million, driven by $17.2 million in higher personnel-related expenses, $9.4 million in higher professional expenses and a $3.5 million increase in other expenses.

The net loss of $94.2 million included $14.9 million of stock-based compensation, against $7.4 million in the prior-year quarter. Nine-month net loss reached $270.5 million versus $214.4 million a year earlier.

Cash and cash equivalents stood at $361.9 million with $924.2 million in marketable securities. Total assets were $1.312 billion against $937.9 million at 31 December 2025. Accumulated deficit widened to $1.411 billion from $1.140 billion. Shares outstanding were 27.9 million, while weighted average diluted shares for the quarter were 29.2 million.

Analysis — What It Means for Healthcare and Biotech Markets

The loss per share narrowed to $3.23 from $3.36 despite the larger net loss, because the weighted average share count rose to 29.2 million from 22.0 million. That is dilution doing the work, and it is the trade-off investors accept when a company raises equity ahead of regulatory decisions rather than after them.

The spending mix is the more telling signal. Research and development is roughly flat while general and administrative nearly quadruples, which is the accounting signature of a company building a sales infrastructure before it has a product to sell. The company said the ulixacaltamide field sales force hiring should finish in the fourth quarter of 2026, so that line item likely stays elevated into the relutrigine decision date.

A counter-argument worth weighing: a PDUFA date is a target, not an approval. The FDA can extend review, request additional data or issue a complete response letter, and the company disclosed no information about the status of either review beyond the dates themselves. Cash runway into 2028 covers both decision windows, but a negative outcome would leave commercial infrastructure without a product to support.

Positioning around PRAX will likely track the two dates rather than the quarterly print. The company also reinitiated the long-term safety study tied to the Essential3 program and started a July 2026 collaboration with Remagine Labs to develop a transdermal patch of ulixacaltamide, extending the franchise beyond the pill formulation.

Outlook — What to Watch Next

The near-term calendar is dense. The company hosts an Investor Day in New York on 12 November 2026 at 8:00 AM ET, covering commercial strategy and launch readiness for both programs under review. Topline results from the EMERALD study of relutrigine in broad DEEs are expected in the fourth quarter of 2026.

The first regulatory gate is the relutrigine PDUFA date of 27 December 2026, followed by ulixacaltamide on 29 January 2027. Between those, the company expects to complete field sales force hiring for ulixacaltamide in the fourth quarter.

Further out, enrollment in the EMBRAVE3 registrational trial of elsunersen continues, with topline results anticipated in 2027. The POWER2 study of vormatrigine has restarted after design updates drawn from the POWER1 Phase 2/3 study, and the company expects to initiate the monotherapy POWER3 study in 2027.

The company did not disclose pricing, launch timing beyond the PDUFA dates, or any commercial revenue assumptions for either candidate.

Frequently Asked Questions

What does the Praxis Precision Medicines cash position mean for shareholders?

The $1.3 billion balance at 30 September 2026 is up $359.9 million from $926.1 million at 31 December 2025, and the company says it funds operations into 2028. For shareholders, that removes near-term financing risk across both FDA decision windows. It does not remove clinical or regulatory risk, and it reflects dilution from the January 2026 offering, with weighted average diluted shares rising to 29.2 million from 22.0 million a year earlier.

Why did Praxis general and administrative expenses jump so much?

General and administrative expenses rose to $42.7 million from $12.6 million a year earlier, a $30.1 million increase. The company attributed $17.2 million to higher personnel-related expenses, $9.4 million to higher professional expenses and $3.5 million to other expenses. The increase lines up with commercial buildout: the relutrigine team is fully hired and the ulixacaltamide sales force is expected to be complete this quarter, all before any product revenue exists.

What happens if the FDA misses the PDUFA target dates?

A PDUFA target action date is the FDA's internal goal, not a guarantee. The agency can extend review, request more data or issue a complete response letter. Praxis disclosed the dates, 27 December 2026 for relutrigine and 29 January 2027 for ulixacaltamide, but gave no detail on review status. The company's stated cash runway into 2028 covers both windows, so a delay would not immediately threaten funding.

Bottom Line

Praxis is spending to build two commercial launches against FDA decisions due within three months of each other.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.